JP2024099886A - Hgf production promoter and method for producing the same - Google Patents
Hgf production promoter and method for producing the same Download PDFInfo
- Publication number
- JP2024099886A JP2024099886A JP2023003490A JP2023003490A JP2024099886A JP 2024099886 A JP2024099886 A JP 2024099886A JP 2023003490 A JP2023003490 A JP 2023003490A JP 2023003490 A JP2023003490 A JP 2023003490A JP 2024099886 A JP2024099886 A JP 2024099886A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- hgf
- hgf production
- production
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、諸疾患の改善に有効であるＨＧＦ（肝細胞増殖因子：Hepatocytes Growth Factor、以下ＨＧＦと略する）産生促進作用を有するＨＧＦ産生促進剤に関する。更に詳しくは、ハス胚芽、オタネニンジン、タチアワユキセンダングサ、スギナ、ヨモギ及びネズミモチの混合抽出物及びその製造方法に関する。 The present invention relates to an HGF (Hepatocyte Growth Factor, hereinafter abbreviated as HGF) production promoter having an action of promoting the production of HGF, which is effective in improving various diseases. More specifically, the present invention relates to a mixed extract of lotus germ, Panax ginseng, Bidens pilosa, Equisetum arvense, Artemisia princeps, and Ligustrum arvensis, and a method for producing the same.
ＨＧＦは、初代培養肝細胞の増殖を強く促進する因子として精製されたサイトカインであり、肝臓再生力を支える必要な肝再生因子である。ＨＧＦは分子量が約９万の一本鎖のタンパク質である。 HGF is a cytokine that has been purified as a factor that strongly promotes the proliferation of primary cultured hepatocytes, and is an essential liver regeneration factor that supports the liver's regenerative power. HGF is a single-chain protein with a molecular weight of approximately 90,000.
ＨＧＦは、間葉細胞によって分泌され、多機能サイトカインとして、主に上皮由来細胞に対して作用する。ＨＧＦが、細胞増殖促進、細胞死抑制、組織修復、形態形成、血管新生、腫瘍伝播、ウィルス感染の免疫調節、及び心血管代謝活動を担う多様な機能を持っており、様々な疾患を対象に治療応用のための研究開発が進められてきた。 HGF is secreted by mesenchymal cells and acts as a multifunctional cytokine mainly on epithelial-derived cells. HGF has a variety of functions, including promoting cell proliferation, inhibiting cell death, tissue repair, morphogenesis, angiogenesis, tumor propagation, immunoregulation of viral infections, and cardiometabolic activity, and research and development has been conducted for its therapeutic application in various diseases.
ＨＧＦは多彩な生理機能を有することが知られている。ＨＧＦが、肝臓、心臓、血管、脳、腎臓、消化器、皮膚、肺、及び神経等様々な組織や器官に対して再生又は保護作用を有しており、またこれらの組織や器官における諸疾患の改善にも有効であることが多数報告されている。ＨＧＦタンパク量を増やすことで、健康維持に役立つと期待できるため、現在ＨＧＦを外因的に補充し、様々の疾病の治療に用いられるように試みるなどの取り組みが行われている。また、ＨＧＦ産生促進作用を有している食品や生薬などの研究も進められている。 HGF is known to have a variety of physiological functions. It has been reported that HGF has regenerative and protective effects on various tissues and organs, such as the liver, heart, blood vessels, brain, kidneys, digestive system, skin, lungs, and nerves, and is also effective in improving various diseases in these tissues and organs. Increasing the amount of HGF protein is expected to help maintain health, so efforts are currently being made to exogenously supplement HGF and use it to treat various diseases. Research is also underway into foods and herbal medicines that promote HGF production.
これまで、ガゴメコンプ由来フコイダン（特許文献１）、アンジオテンシン変換酵素阻害剤及びアンジオテンシンII受容体拮抗薬（特許文献２）及び生薬の混合物（特許文献３）が、ＨＧＦ産生促進剤として知られている。一方、冬虫夏草粉砕物及びその抽出成分（特許文献４）、ニガウリ加工物の有効成分（特許文献５）から得られた成分が、ＨＧＦ産生促進活性を有することが分かってきた。また、プロテインキナーゼA（PKA）阻害剤の一種である8-Bromo-cAMPにＨＧＦ産生促進作用が確認され、研究時に陽性対照としてよく使われている（非特許文献１）。 To date, fucoidan derived from Kagome comp (Patent Document 1), angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists (Patent Document 2), and a mixture of herbal medicines (Patent Document 3) are known as HGF production promoters. On the other hand, it has been found that ingredients obtained from crushed Cordyceps sinensis and its extracts (Patent Document 4) and active ingredients of bitter melon processed products (Patent Document 5) have HGF production promoting activity. In addition, 8-Bromo-cAMP, a type of protein kinase A (PKA) inhibitor, has been confirmed to have an HGF production promoting effect, and is often used as a positive control in research (Non-Patent Document 1).
ハス胚芽は、インド原産のハス科多年生水性植物であるハスの実の殻を除いた微小部分である。発芽成長に必要な成分を凝縮していると言われる。ハス胚芽抽出物の薬理作用を明らかにする研究は数多く行われ、抗肥満作用、抗がん作用、抗炎症作用が確認されている。 Lotus germ is a tiny part of the seed of the lotus plant, a perennial aquatic plant of the Nelumbaceae family native to India, with the husk removed. It is said to contain concentrated ingredients necessary for germination and growth. Numerous studies have been conducted to clarify the pharmacological effects of lotus germ extract, and anti-obesity, anti-cancer, and anti-inflammatory effects have been confirmed.
オタネニンジンは学名がPanax ginseng C.A.Mey.である。ニンジンの有効成分には、非常に高い滋養強壮の効果があり、また記憶過程の改善、抗ストレス、消化管運動亢進、ストレス性胃潰瘍抑制、抗アレルギーなどの作用も報告されている。 The scientific name of ginseng is Panax ginseng C.A.Mey. The active ingredients in ginseng have a highly nourishing and strengthening effect, and it has also been reported to improve memory processes, act as an anti-stress agent, increase gastrointestinal motility, inhibit stress-induced gastric ulcers, and act as an anti-allergic agent.
タチアワユキセンダングサは、キク科センダングサ属の植物である。過酷な環境でも繁殖能力が高く、非常に強い生命力を持つことが特徴である。日本では、沖縄などのほか、中南米諸国やアフリカ、中国、台湾などにも分布している。昔から伝承薬、民間薬として広く使用されている。 Bidens frondosa is a plant of the Asteraceae family. It is characterized by its high reproductive ability even in harsh environments and its extremely strong vitality. In Japan, it is found in Okinawa and other areas, as well as in Central and South America, Africa, China, Taiwan, and other places. It has been widely used as a traditional medicine and folk remedy since ancient times.
スギナは、シダ植物門トクサ網トクサ目トクサ科トクサ属の植物の1種である。生薬として、古くから伝承されていたが、花粉症対策としての効能があると最近の研究で分かってきた。 Horsetail is a species of plant in the genus Equisetum, order Equisetum, and family Equisetaceae. It has been handed down since ancient times as a herbal medicine, but recent research has revealed its efficacy in treating hay fever.
ヨモギは、キク科の多年草で、灸のもぐさ、漢方薬の原料としてよく使われている。特有の香りがあり、若い葉は食用され、生薬は止血、干した葉は健胃、下痢、貧血など多くの薬効があるとされる。 Mugwort is a perennial plant of the Asteraceae family that is often used as moxa for moxibustion and as an ingredient in traditional Chinese medicine. It has a distinctive fragrance, and the young leaves are edible. The raw herb is said to stop bleeding, and the dried leaves have many medicinal properties, such as stomach tonic, diarrhea, and anemia.
ネズミモチは、「女貞子」とも呼ばれ、主に中国で栽培されるモクセイ科の植物である。古くから耳鳴改善、白内障予防、白髪予防、リラックス作用などとして使用されているが、近年骨粗鬆症の予防、抗糖尿病、肝機能改善など研究で知らされてきた。 Also known as "female sedum," Nezumimochi is a plant of the Oleaceae family that is mainly cultivated in China. It has long been used to improve tinnitus, prevent cataracts and gray hair, and for its relaxing properties, but in recent years research has revealed that it can also help prevent osteoporosis, fight diabetes, and improve liver function.
ＨＧＦ産生促進に寄与するのが体内物質のみならず、植物などでも促進することができると分かってきている。また、陽性対照である8-Bromo-cAMPは試験・研究の目的のみに使用される試薬であり、ヒトが摂取することは禁じられており、本発明は、安全性が担保されている植物を用いて、高いＨＧＦ産生促進作用を有するＨＧＦ産生促進剤を提供することとなる。 It has become clear that not only substances in the body but also plants can promote HGF production. Furthermore, the positive control, 8-Bromo-cAMP, is a reagent used only for testing and research purposes and is prohibited for human consumption. The present invention uses plants, the safety of which is guaranteed, to provide an HGF production promoter with a high HGF production promoting effect.
様々な植物のＨＧＦ産生促進作用を検討しているうちに、それらの組み合わせの相乗効果などを鋭意検討した結果、請求項１記載のＨＧＦ産生促進剤に極めて強いＨＧＦ産生促進作用を有していることを見出し、本発明に至った。 While investigating the HGF production promoting effect of various plants, we conducted extensive research into the synergistic effects of combinations of these plants, and as a result, we discovered that the HGF production promoter described in claim 1 has an extremely strong HGF production promoting effect, which led to the present invention.
本発明は、植物由来のＨＧＦ産生促進作用を有する混合抽出物、すなわち、請求項１の混合抽出物が、ハス胚芽１０ｍｇ～１０ｇ重量部、オタネニンジン１０ｍｇ～１０ｇ重量部、タチアワユキセンダングサ１０ｍｇ～１０ｇ重量部、スギナ１０ｍｇ～１０ｇ重量部、ヨモギ１０ｍｇ～１０ｇ重量部及びネズミモチ１０ｍｇ～１０ｇ重量部の混合抽出物である。 The present invention relates to a mixed extract derived from plants that has an effect of promoting HGF production, i.e., the mixed extract of claim 1 is a mixed extract of 10 mg to 10 g by weight of lotus germ, 10 mg to 10 g by weight of ginseng, 10 mg to 10 g by weight of Bidens pilosa, 10 mg to 10 g by weight of horsetail, 10 mg to 10 g by weight of mugwort, and 10 mg to 10 g by weight of Ligustrum arvensis.
本発明により、高いＨＧＦ産生促進効果を有するＨＧＦ産生促進剤を提供することが可能である。本発明は、細胞などに直接作用し、ＨＧＦ産生促進効果を発揮するものである。十分なＨＧF産生促進効果を発揮し、健康維持に役立つと期待できる。 The present invention makes it possible to provide an HGF production promoter that has a high HGF production promoting effect. The present invention acts directly on cells and the like, and exerts an HGF production promoting effect. It exerts a sufficient HGF production promoting effect, and is expected to be useful for maintaining health.
本発明は、ＨＧＦ産生促進作用を用いる植物、即ちハス胚芽、オタネニンジン、タチアワユキセンダングサ、スギナ、ヨモギ及びネズミモチの混合抽出物である。以下、本発明を実施するための形態について詳細に説明する。 The present invention relates to a mixed extract of plants that promote HGF production, namely lotus germ, ginseng, Bidens pilosa, horsetail, mugwort and Ligustrum japonicum. The following is a detailed description of the mode of carrying out the present invention.
本発明は、ＨＧＦ産生促進作用をもつ植物、すなわちハス胚芽、オタネニンジン、タチアワユキセンダングサ、スギナ、ヨモギ及びネズミモチを含む混合抽出物を用いることが望ましい。 In the present invention, it is preferable to use a mixed extract containing plants that have an effect of promoting HGF production, namely lotus germ, ginseng, Bidens pilosula, horsetail, mugwort and Ligustrum arvensis.
ハス胚芽、中国産でも日本産でも使用することができる。中国産のハス胚芽をそのまま又は乾燥しているものが望ましい。 Lotus germ can be used whether it is from China or Japan. It is preferable to use Chinese lotus germ, either whole or dried.
オタネニンジンは、葉、茎、根などの部分を使用することに問題ないが、根又は茎をそのまま又は乾燥しているものが望ましい。 It is okay to use any part of ginseng, such as the leaves, stems, or roots, but it is preferable to use the roots or stems, either whole or dried.
タチアワユキセンダングサは、日本、中国、台湾、インドなどの産地のタチアワユキセンダングサの葉及び茎をそのまま又は乾燥しているものを使用してもよいが、葉及び茎をそのまま又は乾燥しているもので、かつ日本産が望ましい。 The leaves and stems of Bidens pilosa grown in Japan, China, Taiwan, India, or other areas may be used either whole or dried, but it is preferable that the leaves and stems are whole or dried and that they are from Japan.
スギナは、葉、茎、根などの部分を使用することに問題ないが、葉及び茎をそのまま又は乾燥しているものが望ましい。 It is okay to use any part of horsetail, including the leaves, stems, and roots, but it is preferable to use the leaves and stems whole or dried.
ヨモギは、葉も茎も使用することには問題ないが、葉をそのまま又は乾燥しているものが望ましい。 There is no problem using both the leaves and stems of mugwort, but it is preferable to use the leaves as is or dried.
ネズミモチは、実の部分を使用することに問題ないが、そのまま又は乾燥しているものが望ましい。 There is no problem with using the fruit of Nezumimochi, but it is preferable to use it whole or dried.
ＨＧＦ産生促進作用を調べるのに、上皮細胞や内皮細胞、さらに一部の間葉系細胞（腎尿細管上皮細胞、乳腺上皮細胞、気管支上皮細胞、胆管上皮細胞、ケラチノサイト、メラノサイト、血管内皮細胞、線維芽細胞、軟骨細胞、破骨細胞、筋衛星細胞など）も使用することができるが、線維芽細胞を用いて検討することが望ましい。 To investigate the effect of promoting HGF production, epithelial cells, endothelial cells, and even some mesenchymal cells (renal tubular epithelial cells, mammary epithelial cells, bronchial epithelial cells, bile duct epithelial cells, keratinocytes, melanocytes, vascular endothelial cells, fibroblasts, chondrocytes, osteoclasts, muscle satellite cells, etc.) can be used, but it is preferable to use fibroblasts for the study.
本発明で用いられる抽出物は、上記した６種類の植物をそのまま又は裁断、混合物を抽出溶媒にて調製することができる。 The extracts used in the present invention can be prepared by using the six types of plants listed above as is or by cutting or mixing them with an extraction solvent.
乾燥粉砕物は、それぞれの植物を乾燥した後粉砕するか、又は細かく切断した後に乾燥することによって調製することが可能である。乾燥方法としては、それぞれの植物の成分を破壊しない範囲であれば特に制限がないが、真空凍結乾燥、熱風乾燥、遠赤外線乾燥、減圧乾燥、マイクロ波減圧乾燥、及び加熱蒸気乾燥等を広く用いることができる。その中でも、成分の安定性が高く担保できる真空乾燥方法を用いることが望ましい。 Dried and pulverized materials can be prepared by drying and pulverizing each plant, or by cutting and drying each plant. There are no particular limitations on the drying method as long as it does not destroy the components of each plant, but a wide range of methods can be used, including vacuum freeze drying, hot air drying, far-infrared drying, reduced-pressure drying, microwave reduced-pressure drying, and heated steam drying. Of these, it is preferable to use the vacuum drying method, which can ensure a high level of stability of the components.
抽出溶媒には、水、エタノール及びこれらの混合液が安全上望ましいが、抽出溶媒を完全留去して乾燥粉末を作る場合には、メタノールやブタノールなど低級アルキルアルコール、あるいはアセトン、DMSOなどの溶媒を使用することができる。 For safety reasons, water, ethanol, and mixtures of these are preferable as extraction solvents, but if the extraction solvent is to be completely removed to produce a dry powder, solvents such as lower alkyl alcohols such as methanol and butanol, or acetone and DMSO can be used.
抽出溶媒を植物又は植物の混合物に対して１～１００倍量、通常、常温～100℃又は常圧下で１～６時間浸漬した後に濾過して抽出物を得ることができるが、抽出溶媒を１０～３０倍、８0～100℃で常圧下で１～３時間という条件が望ましい。 The extract can be obtained by soaking the plant or plant mixture in 1 to 100 times the amount of extraction solvent, usually at room temperature to 100°C or under normal pressure for 1 to 6 hours, and then filtering, but the most preferable conditions are 10 to 30 times the amount of extraction solvent, 80 to 100°C, and normal pressure for 1 to 3 hours.
本発明における混合抽出物の各植物の配合は、乾燥重量として、ハス胚芽１０ｍｇ～１００ｇ重量部、オタネニンジン１０ｍｇ～１００ｇ重量部、タチアワユキセンダングサ１０ｍｇ～１００ｇ重量部、スギナ１０ｍｇ～１００ｇ重量部、ヨモギ１０ｍｇ～１００ｇ重量部及びネズミモチ１０ｍｇ～１００ｇ重量部の割合で混合されることができるが、ハス胚芽１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）、オタネニンジン１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）、タチアワユキセンダングサ１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）、スギナ１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）、ヨモギ１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）及びネズミモチ１ｇ～１０ｇ重量部（１，２，３，４，５，６，７，８，９ｇ重量部）の割合で混合されることが望ましい。 The composition of each plant in the mixed extract of the present invention can be mixed in the following proportions, in terms of dry weight: lotus germ 10mg-100g parts by weight, ginseng 10mg-100g parts by weight, Bidens truncatula 10mg-100g parts by weight, horsetail 10mg-100g parts by weight, mugwort 10mg-100g parts by weight, and Ligustrum nigra 10mg-100g parts by weight. It is desirable to mix them in the following ratios: up to 10g parts by weight (1,2,3,4,5,6,7,8,9g parts by weight), Bidens dulcis var. 1g to 10g parts by weight (1,2,3,4,5,6,7,8,9g parts by weight), Equisetum arvense 1g to 10g parts by weight (1,2,3,4,5,6,7,8,9g parts by weight), Artemisia vulgaris 1g to 10g parts by weight (1,2,3,4,5,6,7,8,9g parts by weight), and Ligustrum nigra 1g to 10g parts by weight (1,2,3,4,5,6,7,8,9g parts by weight).
このようにして得られる混合抽出物は、後述の実施例で示すように、強いＨＧＦ産生促進作用を有している。 The mixed extract obtained in this manner has a strong effect of promoting HGF production, as shown in the examples below.
本発明に用いられている植物の混合抽出物は、６種類の植物の組み合わせによって作られている。 The mixed plant extract used in this invention is made from a combination of six different plants.
以下、実施例を用いて本発明をより詳細に説明する。但し、本発明はこれらの実施例によって制限されるものではない。 The present invention will be described in more detail below using examples. However, the present invention is not limited to these examples.
１．調製例
［調製例１：単一植物の抽出物の調製］
表１に示している２２種類の乾燥した状態の植物を細かく裁断してから粉砕した。粉砕したそれぞれの乾燥物を４０ｇに対して水を６００ｍｌ加え、１５倍希釈した。その後、水浴上で１００℃、２時間還流熱水抽出を行った。抽出後、放冷してから濾紙でろ過を行った。ろ過により必要に応じ沈殿物を除き、得られた濾過液をエバポレーターで減圧濃縮し、得られた抽出物を乾燥減量が約４０～６０％くらいになるように調整した。その後、４℃の冷蔵庫にて保存した。
1. Preparation Examples [Preparation Example 1: Preparation of a Single Plant Extract]
The 22 types of dried plants shown in Table 1 were finely cut and then crushed. 600 ml of water was added to 40 g of each crushed dried material, resulting in a 15-fold dilution. Then, hot water extraction was performed at 100°C reflux in a water bath for 2 hours. After extraction, the mixture was allowed to cool and then filtered through filter paper. Precipitates were removed by filtration as necessary, and the resulting filtrate was concentrated under reduced pressure using an evaporator, and the resulting extract was adjusted so that the loss on drying was about 40-60%. Then, it was stored in a refrigerator at 4°C.
［調製例２：混合植物の抽出物の調製］
エキス１～６（配合の内訳は表２を参照）に用いられている各植物を乾燥した状態にした上で混合し、細かく裁断してから粉砕した。粉砕した各種の混合物を４０ｇに対して水を６００ｍｌ加え、１５倍希釈した。その後、水浴上で１００℃、２時間還流熱水抽出を行った。抽出後、放冷してから濾紙でろ過を行った。ろ過により必要に応じ沈殿物を除き、得られた濾過液をエバポレーターで減圧濃縮し、得られた抽出物を乾燥減量が約４０～６０％になるように調整した。その後、４℃の冷蔵庫にて保存した。
[Preparation Example 2: Preparation of mixed plant extract]
The plants used in Extracts 1 to 6 (see Table 2 for the composition) were mixed in a dried state, finely chopped, and then pulverized. 600 ml of water was added to 40 g of each pulverized mixture, resulting in a 15-fold dilution. Then, hot water extraction was performed at 100°C in a water bath under reflux for 2 hours. After extraction, the mixture was allowed to cool and then filtered through filter paper. Precipitates were removed by filtration as necessary, and the resulting filtrate was concentrated under reduced pressure using an evaporator, and the resulting extract was adjusted so that the loss on drying was approximately 40 to 60%. Then, the mixture was stored in a refrigerator at 4°C.
２．実験操作
後述する実験例で使用した実験操作を説明する。
2. Experimental Procedures The experimental procedures used in the experimental examples described below are explained below.
［実験操作１：ヒト皮膚線維芽細胞培養法］
ＨＧＦ産生促進活性を測定するのに、ヒト皮膚線維芽細胞（MRC-5）を用いて測定した。MRC-5の培養は、１０重量％の牛胎児血清（ＦＢＳ）（Cytiva社）を添加したE-MEM（Wako社）培地で、３７℃、５％ＣＯ２インキュベータで実施した。MRC-5細胞は、４.５６×１０４／ｍｌになるように調製し、１２ウェルプレートに播種した。陽性対照としては、8-Bromo-cAMP １ｍＭ（Selleck Chemicals社）を用い、コントロールは１０重量％のＦＢＳを添加したE-MEM培地を用いた。
[Experimental Procedure 1: Human Skin Fibroblast Cell Culture Method]
Human dermal fibroblasts (MRC-5) were used to measure the HGF production promoting activity. MRC-5 cells were cultured in E-MEM (Wako) medium supplemented with 10% by weight of fetal bovine serum (FBS) (Cytiva) at 37°C in a 5% CO2 incubator. MRC-5 cells were prepared to a density of 4.56 x 104 /ml and seeded on a 12-well plate. 8-Bromo-cAMP 1 mM (Selleck Chemicals) was used as a positive control, and E-MEM medium supplemented with 10% by weight of FBS was used as a control.
［実験操作２：試薬添加、培養上清回収方法］
１２ウェルプレートに細胞を添加して２４時間後に、様々の濃度の調製例１～２の抽出物を含む１０重量％のＦＢＳを添加したE-MEM培地を添加し、さらに培養して２４時間後、培養上清を回収した。
[Experimental Procedure 2: Method for adding reagents and recovering culture supernatant]
24 hours after the cells were added to the 12-well plate, E-MEM medium supplemented with 10% by weight FBS containing various concentrations of the extracts of Preparation Examples 1 and 2 was added, and after further culturing for 24 hours, the culture supernatant was collected.
３．実験例
［実験例１：培養上清のＨＧＦ量の測定方法］
実験操作２にて回収した培養上清をELISA法でＨＧＦ産生量を測定した。ELISAは市販しているR&D社のELISA Kit(DHG00B)を使用した。得られた値を各培養液中の肝細胞増殖因子量を示し、また陽性対照として8-Bromo-cAMP １ｍＭを用いた。
3. Experimental Examples [Experimental Example 1: Method for measuring HGF amount in culture supernatant]
The amount of HGF produced was measured by ELISA using the culture supernatant collected in Experimental Procedure 2. A commercially available ELISA kit (DHG00B) from R&D was used for the ELISA. The obtained values indicate the amount of hepatocyte growth factor in each culture medium, and 8-Bromo-cAMP 1 mM was used as a positive control.
［実験例２：２２種類の植物、６種の混合抽出物がＨＧＦ産生に及ぼす影響］
表１で示しているように、それぞれ単独の抽出物（２２種類）と６種類の混合抽出物のＨＧＦ産生量をELISAで測定した後に、陽性対照8-Bromo-cAMP １ｍＭと同じ産生誘導濃度として算出した。算出値が低ければ低いほど、ＨＧＦ産生誘導活性が高いということである。表３に示しているように、２２種類の植物の中では、高いＨＧＦ産生促進作用を示したのが、ハス胚芽、オタネニンジン、タチアワユキセンダングサ、スギナ、ヨモギ及びネズミモチの６種類であった。そこで、６種類の植物の混合抽出物（表２のエキス３）のＨＧＦ産生促進活性を測定した結果、それぞれの単独植物の抽出物よりも高いＨＧＦ産生促進活性を示し、ほかの植物の組み合わせにより作られた混合抽出物よりも高いＨＧＦ産生促進活性を有することが分かった（図１）。また、図２に示しているように、エキス３は濃度依存的に顕著なＨＧＦ産生促進効果があった。
[Experimental Example 2: Effects of 22 types of plants and 6 types of mixed extracts on HGF production]
As shown in Table 1, the amount of HGF produced by each of the 22 individual extracts and the 6 mixed extracts was measured by ELISA, and then calculated as the same production induction concentration as the positive control 8-Bromo-cAMP 1 mM. The lower the calculated value, the higher the HGF production induction activity. As shown in Table 3, among the 22 plants, the 6 plants that showed high HGF production promotion activity were lotus germ, ginseng, Bidens pilosula, Equisetum arvense, Artemisia princeps, and Ligustrum arvensis. The HGF production promotion activity of the 6 mixed extracts (Extract 3 in Table 2) was measured, and it was found to have a higher HGF production promotion activity than the extracts of each individual plant, and a higher HGF production promotion activity than the mixed extracts made by combining other plants (Figure 1). Also, as shown in Figure 2, Extract 3 had a significant HGF production promotion effect in a concentration-dependent manner.
本発明は、６種類の植物の混合抽出物のＨＧＦ産生促進剤は、健康食品、機能性食品又はサプリメントとして有利に利用し、健康維持に役に立つと期待できる。
The present invention provides an HGF production promoter, which is a mixed extract of six types of plants, that can be advantageously used as a health food, functional food or supplement and is expected to be useful in maintaining health.
すなわち、請求項１の混合抽出物は、ハス胚芽１０ｍｇ～１０ｇ重量部、オタネニンジン１０ｍｇ～１０ｇ重量部、タチアワユキセンダングサ１０ｍｇ～１０ｇ重量部、スギナ１０ｍｇ～１０ｇ重量部、ヨモギ１０ｍｇ～１０ｇ重量部及びネズミモチ１０ｍｇ～１０ｇ重量部の混合抽出物である。 That is, the mixed extract of claim 1 is a mixed extract of 10 mg to 10 g parts by weight of lotus germ, 10 mg to 10 g parts by weight of Panax ginseng, 10 mg to 10 g parts by weight of Bidens pilosa, 10 mg to 10 g parts by weight of Equisetum arvense, 10 mg to 10 g parts by weight of Artemisia princeps, and 10 mg to 10 g parts by weight of Ligustrum arvensis.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003490A JP7553216B2 (en) | 2023-01-13 | 2023-01-13 | HGF production promoter and method for producing same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023003490A JP7553216B2 (en) | 2023-01-13 | 2023-01-13 | HGF production promoter and method for producing same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024099886A true JP2024099886A (en) | 2024-07-26 |
| JP7553216B2 JP7553216B2 (en) | 2024-09-18 |
Family
ID=91958454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023003490A Active JP7553216B2 (en) | 2023-01-13 | 2023-01-13 | HGF production promoter and method for producing same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP7553216B2 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009269927A (en) * | 2000-04-10 | 2009-11-19 | Takara Bio Inc | Therapeutic substance |
| JP3213508U (en) * | 2017-06-30 | 2017-11-16 | 株式会社ｋｉｍｉｔａｎ ｈｏｕｓｅ | Dietary herbal materials with enhanced constitution improving effect, and constitution improving staple food and side food ingredients containing the same |
| JP2019099504A (en) * | 2017-12-01 | 2019-06-24 | 日本メナード化粧品株式会社 | Hair follicle cell activator |
-
2023
- 2023-01-13 JP JP2023003490A patent/JP7553216B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009269927A (en) * | 2000-04-10 | 2009-11-19 | Takara Bio Inc | Therapeutic substance |
| JP3213508U (en) * | 2017-06-30 | 2017-11-16 | 株式会社ｋｉｍｉｔａｎ ｈｏｕｓｅ | Dietary herbal materials with enhanced constitution improving effect, and constitution improving staple food and side food ingredients containing the same |
| JP2019099504A (en) * | 2017-12-01 | 2019-06-24 | 日本メナード化粧品株式会社 | Hair follicle cell activator |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7553216B2 (en) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009132662A (en) | Glutathione production promoter | |
| KR20010025178A (en) | Extracts derived from Pueraria mirifica, Butea superba and/or Mucuna collettii and extraction thereof, foods, beverages, pharmaceutical products and/or cosmetics containing the extracts as an active ingredient and manufacturing thereof | |
| KR20180110939A (en) | Composition for preventing hair loss and promoting hair growth comprising plant extract | |
| KR101224238B1 (en) | Extract of mixed plants | |
| CN103948619B (en) | Application of vaccarin for resisting oxidation and high-glucose damage | |
| Sahu et al. | A mini-review on phytochemical screening, biological activity, and therapeutic capability of Hibiscus: An ornamental plant species | |
| KR102249711B1 (en) | Composition for enhancing skin elasticity or improving skin wrinkels comprising enzyme treated extract of leguminous plants cultured root | |
| JP7553216B2 (en) | HGF production promoter and method for producing same | |
| KR100949482B1 (en) | Phamaceutical composition of diabetes mellitus or hypertension using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN113413419A (en) | Ovary care composition containing jujube exosome and preparation method thereof | |
| KR100964603B1 (en) | Phamaceutical composition of diabetes mellitus using extract of taxus cuspidata and mulberry tree, and mamufacturing method thereof | |
| CN102643327A (en) | Preparation method and application of polypeptide of fermented cucumber seeds | |
| KR102478898B1 (en) | Saururus chinensis extract using oriental processing and its use for external skin | |
| KR102289257B1 (en) | Food composition for improving menopausal symptoms | |
| KR100885480B1 (en) | Herbal whitening composition and preparation method thereof | |
| KR101658333B1 (en) | BCA composite and a serum for hair-loss | |
| KR101795261B1 (en) | Medicinal-Herb Composition Comprising Chinese matrimony vine for Treatmenting and Protecting the Insomniac and the Method of Making the Same | |
| JP2019147824A (en) | Kaempferia parviflora-containing compositions | |
| KR101723962B1 (en) | Atopic dermatitis mitigate functional composition using environmentally friendly natural ingredients | |
| KR20070101660A (en) | Wipes composition containing a mixed extract of birch sap and rhubarb | |
| KR102588877B1 (en) | Injection liquid composition for localized lipolysis and Administration method of the same | |
| KR20180092438A (en) | Composition for promoting hair growth and the method thereof | |
| CN104738299A (en) | Preparation method of radix cynanchi bungei honey slice and product prepared by method | |
| CN103919831B (en) | Preparation method and clinical application of herba epimedii derivative transdermal absorbent promoting fracture healing | |
| KR102843808B1 (en) | The cosmetic composition containing Vicia faba-derived PDRN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240220 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20240220 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240527 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240904 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240904 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7553216 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |